The device was developed by a team led by Professor Song Ih Ahn of the Department of Mechanical Engineering at KAIST, in collaboration with researchers at Sungkyunkwan University, CHA Bundang Medical Center, and CHA University. Their work addresses a central problem in glioblastoma treatment: the tumor is not an isolated mass of malignant cells. It exists within a highly complex brain environment shaped by blood vessels, astrocytes, immune cells, and the altered barrier that forms around the tumor. Because anticancer drugs must cross this barrier before reaching tumor cells, the same concentration of a drug may produce very different biological effects depending on how permeable or restrictive that barrier is in an individual patient.

The healthy blood–brain barrier is formed largely by specialized brain endothelial cells that line blood vessels and tightly regulate the movement of molecules between the bloodstream and neural tissue. These cells are supported by astrocytes and other components of the neurovascular unit. Tight junctions between endothelial cells limit the passage of many substances, including numerous therapeutic compounds. When glioblastoma develops, the surrounding vascular system becomes abnormal. The resulting blood–brain tumor barrier may contain regions that are more permeable than a healthy barrier, while other areas remain highly restrictive. This uneven and patient-specific architecture can influence drug delivery, tumor metabolism, resistance mechanisms, and the survival of malignant cells beyond what can be predicted from tumor genetics alone.

To recreate this environment, the researchers constructed a microfluidic chip containing separate but closely connected channels. Brain microvascular endothelial cells, known as HBMECs, were placed in an upper vascular channel, while astrocytes and patient-derived glioblastoma cells were cultured in a lower tissue channel. The arrangement allows researchers to observe how the two compartments interact while measuring the movement of drugs across the engineered barrier. Microfluidic systems use precisely controlled chambers and fluid pathways that can reproduce aspects of blood flow, concentration gradients, and tissue organization on a small scale. The design can also accommodate perivascular and immune cells, creating the possibility of modeling an even broader range of biological interactions within the tumor microenvironment.

The team used tumor cells obtained from three glioblastoma patients to create individual blood–brain tumor barrier models. Each patient had the same IDH-wildtype classification and the same MGMT promoter methylation status, a biomarker commonly used to estimate sensitivity to temozolomide, one of the standard drugs used against glioblastoma. On the basis of conventional clinical testing, the patients might therefore have been expected to respond in broadly similar ways. The researchers then exposed the patient-specific chips to temozolomide and bevacizumab, an antibody that targets vascular endothelial growth factor and is used to influence tumor-associated blood vessels. The experiments allowed the team to evaluate both the ability of the drugs to cross the engineered barrier and their effects on the tumor cells behind it.

The results revealed differences that were not apparent from the shared genetic and biomarker profiles. The three models showed distinct barrier properties, including differences in permeability and electrical resistance, measurements that reflect how tightly the endothelial layer controls transport. They also displayed differences in gene expression and in their responses to the two anticancer agents. In practical terms, the same drug encountered a different biological gateway in each chip. A treatment could therefore be affected not only by whether the tumor cells were intrinsically sensitive to the drug, but also by how efficiently the patient-specific vascular barrier allowed the drug to reach them and how the surrounding cells altered the tumor’s behavior.

The researchers compared the chip findings with the actual clinical courses of the three patients, including progression-free survival and post-progression survival. According to the team, the on-chip barrier characteristics and drug responses closely matched the outcomes observed in the patients. The comparison suggests that the engineered models captured clinically meaningful features of each person’s disease, despite the small number of cases. The result is important because conventional testing often focuses on the cancer cell itself, while the chip evaluates the complete route a treatment must follow: from the vascular channel, across the tumor-associated barrier, and into the tissue containing malignant cells and supporting cells.

The platform could eventually become a tool for testing several therapies from a single patient’s tumor sample before a treatment decision is made. Researchers could expose parallel chips to different drug combinations, doses, or emerging compounds and compare the resulting tumor responses under conditions that more closely resemble the patient’s own disease. Such testing would not replace clinical trials or medical judgment, and the current findings require validation in a substantially larger patient population. The tumors grown on a chip also cannot reproduce every feature of a living brain, including long-range immune responses, systemic drug metabolism, and the full three-dimensional complexity of a patient’s tumor. Nevertheless, incorporating the blood–brain tumor barrier represents a significant advance over models that test drugs only on isolated cancer cells.

The study’s authors say the same approach could also assist pharmaceutical research by providing a human-relevant system for evaluating new drug candidates and studying why treatments fail. The inclusion of perivascular and immune components may make it possible to investigate how blood vessels and immune cells contribute to resistance, invasion, and recurrence. Minsu Ryoo of KAIST and Gaeun Lee of Sungkyunkwan University served as co-first authors. The findings were published in Small on June 27, 2026, and were selected for the journal’s Front Cover. Professor Ahn described the work as a platform for reproducing patient-derived tumor cells together with the blood–brain tumor barrier, with the longer-term goal of developing personalized treatment strategies and a preclinical system for new drug development. If future studies confirm its reproducibility and predictive accuracy, the chip could help move glioblastoma care toward a model in which treatment is selected not only by what a tumor is, but also by the living barrier that determines whether medicine can reach it.

Subject of Research: Patient-specific blood–brain tumor barrier-on-a-chip models for predicting glioblastoma treatment responses

Article Title: Human Blood-Brain Tumor Barrier on a Chip to Investigate Personalized Treatment for Glioblastoma Patients

News Publication Date: 18-Aug-2026

Web References: KAIST; https://doi.org/10.1002/smll.202506712

References: Small, published 27-Jun-2026; DOI: 10.1002/smll.202506712

Image Credits: KAIST

Keywords: glioblastoma, blood–brain tumor barrier, blood–brain barrier, organ-on-a-chip, microfluidics, personalized medicine, temozolomide, bevacizumab, drug response prediction, brain cancer, tumor microenvironment, precision oncology

A major reason for this therapeutic failure is the blood–brain barrier (BBB), a tightly regulated network of endothelial cells, junctional proteins, transport systems, and supporting brain cells that protects neural tissue from potentially harmful substances in the bloodstream. Although this barrier is essential for brain function, it also blocks most anticancer drugs from reaching therapeutic concentrations inside the brain. Glioblastoma can disrupt blood vessels in its central regions, creating areas where the related blood–brain tumor barrier becomes more permeable. However, infiltrative tumor cells at the margins may remain protected by an intact or partially intact BBB, allowing them to survive treatment and seed recurrence.

A comprehensive review published in the Chinese Neurosurgical Journal examines how a new generation of nanomedicines is being designed to address this problem. The article, published on July 1, 2026, explores BBB-aware, stimuli-responsive, and biomimetic nanoparticles developed to transport therapeutic compounds across the BBB and into glioblastoma tissue. The collaborative review was led by Dr. Xueqiong Su of Beijing University of Technology, Professor Yujun Song of the University of Science and Technology Beijing, and Dr. Hao Wang of Capital Medical University. Rather than treating the BBB solely as an obstacle to be bypassed, the authors describe it as a biological system that can be studied, targeted, and exploited for more precise drug delivery.

Nanomedicines are engineered particles that can carry drugs, genetic material, imaging agents, or combinations of therapeutic payloads. Their small size and customizable surfaces allow researchers to alter how they circulate through the body, interact with blood vessels, enter cells, and release their cargo. Lipid nanoparticles can protect fragile molecules and merge with cellular membranes; polymeric nanoparticles can be tuned for controlled degradation; dendrimers offer highly branched structures with numerous chemical attachment sites; and inorganic materials can provide magnetic, optical, or catalytic properties. Biomimetic platforms go a step further by imitating natural biological structures, including cell membranes, exosomes, or lipoproteins, potentially helping particles evade immune clearance and remain in circulation longer.

The review describes both passive and active strategies for guiding these particles toward brain tumors. Passive targeting may take advantage of the enhanced permeability and retention effect, in which abnormal tumor blood vessels allow some nanoparticles to accumulate in tumor tissue more readily than in healthy areas. This effect is inconsistent in human glioblastoma, however, and is often insufficient on its own. Active targeting attempts to improve precision by attaching ligands, antibodies, peptides, or other molecular recognition elements to the nanoparticle surface. These components can bind receptors expressed on BBB endothelial cells or glioblastoma cells, including transferrin receptors, low-density lipoprotein receptor-related protein 1, nutrient transporters, and tumor-associated markers. After binding, nanoparticles may be transported across endothelial cells through receptor-mediated transcytosis or internalized directly by tumor cells.

One of the most technically advanced approaches highlighted in the review involves stimuli-responsive delivery. These systems are designed to remain relatively stable while circulating through the body and release their payload only after encountering a specific trigger. Internal signals can include the acidic environment found in some tumor compartments, elevated levels of reactive oxygen species, altered enzyme activity, or differences in cellular redox conditions. External triggers may include near-infrared light, magnetic fields, ultrasound, or heat. For example, a nanoparticle may contain chemical bonds that break under acidic conditions, a polymer shell that degrades in the presence of oxidative stress, or magnetic components that heat when exposed to an alternating magnetic field. Such mechanisms could provide spatiotemporal control, concentrating drug activity in the tumor while reducing exposure to healthy brain tissue.

These platforms can also combine drug delivery with direct physical or biochemical attacks on cancer cells. Magnetic nanoparticles can generate localized heat during magnetic hyperthermia, damaging tumor cells and potentially increasing their sensitivity to chemotherapy or radiotherapy. Photothermal systems absorb light and convert it into heat, while photodynamic and sonodynamic platforms use light or ultrasound to produce reactive oxygen species that damage membranes, proteins, and DNA. Other nanoparticles are being developed to transport nucleic-acid therapeutics, such as small interfering RNA, messenger RNA, or gene-regulating molecules. This expands the therapeutic toolkit beyond conventional cytotoxic drugs and may allow researchers to silence genes involved in tumor growth, invasion, resistance, or immune suppression.

The clinical translation of these technologies is beginning to move beyond laboratory experiments, although the field remains at an early stage. NanoTherm®, an iron oxide-based magnetic hyperthermia system, has demonstrated how nanoparticles can be used as physical treatment platforms in brain tumors. NU-0129, a gold nanoparticle-based RNA interference therapy, has provided evidence that a nanoparticle system can cross the human BBB and deliver gene-silencing cargo in patients. These examples do not yet represent a broadly effective cure for glioblastoma, but they show that advanced nanomedicine concepts can be tested in humans. The authors argue that future systems may integrate targeting, controlled release, imaging, thermal therapy, immune modulation, and genetic intervention within a single multifunctional platform.

Significant barriers still stand between promising designs and routine clinical care. Nanoparticles must demonstrate long-term safety, predictable biodistribution, reliable penetration into heterogeneous tumors, and consistent performance across patients whose BBB and tumor biology may differ substantially. Manufacturing these complex systems at scale while preserving particle size, surface chemistry, drug loading, and release behavior is also difficult. Regulatory agencies must evaluate not only the active drug but the complete nanoparticle system, including its materials, degradation products, immune effects, and interactions with other treatments. The review identifies biomimetic carriers, multifunctional designs, and artificial intelligence-assisted material discovery as particularly important opportunities. By analyzing large datasets of particle properties, biological responses, and tumor characteristics, artificial intelligence could help researchers identify safer and more effective formulations. BBB-aware nanomedicine therefore represents not a single treatment, but an evolving platform strategy that may eventually make one of neuro-oncology’s most protected and complex targets more accessible.

Subject of Research: Glioblastoma nanomedicine and drug delivery across the blood–brain barrier

Article Title: BBB-aware stimuli-responsive and biomimetic nanomedicines for glioblastoma

News Publication Date: 1-Jul-2026

Web References: https://link.springer.com/article/10.1186/s41016-026-00438-6; https://cnjournal.biomedcentral.com/

References: Chinese Neurosurgical Journal, DOI: https://doi.org/10.1186/s41016-026-00438-6

Image Credits: Sbrandner for Wikimedia Commons

Keywords: Glioblastoma, blood–brain barrier, blood–brain tumor barrier, nanomedicine, nanoparticles, drug delivery, biomimetic nanoparticles, stimuli-responsive nanomedicine, nanotechnology, cancer treatment, magnetic hyperthermia, RNA interference

Glioblastoma remains difficult to treat largely because cancer stem-like cells drive regrowth and therapy resistance. Although median survival has improved to roughly 14 months with modern combinations—including brachytherapy surgery and chemotherapy—long-term control is still rare.

The research team combined analyses of GBM tumor samples with public datasets to map how TRNAU1AP correlates with disease severity. They report that higher TRNAU1AP levels associate with worse patient outcomes, suggesting the protein is not merely a biomarker but an actionable component of tumor biology.

Mechanistically, TRNAU1AP appears to organize into small intracellular clusters via phase-separation–linked behavior. These clusters help sustain the translation of selected selenoproteins, proteins that use selenium-dependent chemistry to protect cells from stress and damage. By maintaining this protective program, GBM cells gain a growth advantage.

A second key player in the pathway is IGF2BP3, an m6A “reader” protein. IGF2BP3 recognizes m6A-modified mRNAs—where “m6A” is an N6-methyladenosine epigenetic-like label added to RNA—and shields them from degradation. In GBM, IGF2BP3 binds TRNAU1AP transcripts bearing m6A marks, stabilizing the mRNA and supporting continued TRNAU1AP protein production.

This sets up a coherent therapeutic logic: interrupt the IGF2BP3–TRNAU1AP axis to reduce TRNAU1AP abundance, destabilize the selenoprotein translation program, and increase tumor cell sensitivity to treatment. The authors propose that targeting the pathway could “open up new pathways” to combat a disease that has resisted many approaches.

Next steps focus on drug development—specifically, creating inhibitors of IGF2BP3 capable of crossing the blood–brain barrier. A small-molecule that disrupts IGF2BP3–RNA interactions could lower transcript stability and suppress glioblastoma growth.

Overall, the study reframes GBM progression around RNA-label recognition and phase-separation-linked protein organization, offering a viral-science-news–worthy target for future translational strategies.

Subject of Research: Glioblastoma (GBM) molecular vulnerability via TRNAU1AP and IGF2BP3–m6A regulation
Article Title: Phase separation of TRNAU1AP protein sustains selenoprotein translation and promotes glioblastoma tumorigenesis
News Publication Date: 2-May-2026
Web References: http://dx.doi.org/10.1093/neuonc/noag097
References: 10.1093/neuonc/noag097
Image Credits: Not provided

Keywords: glioblastoma; TRNAU1AP; IGF2BP3; m6A; RNA stability; phase separation; selenoprotein translation; blood–brain barrier; cancer stem cells